Inter- and intra-day variability in β-Glucocerebrosidase activity and pathway biomarkers in healthy volunteers and patients with Parkinson’s disease with a GBA1 mutation
Objective: Characterize inter- and intra-day variability of β-glucocerebrosidase (GCase) activity, using a live-cell assay, and glucosyl-β sphingosine levels in healthy volunteers (HVs) and Parkinson’s disease…Nocturnal Use of Add-On Medications for Parkinson’s Disease: Post Hoc Analysis of the COSMOS Study
Objective: To assess nighttime use of add-on medications for Parkinson’s disease (PD) in a post hoc analysis of the COSMOS (COmedication Study assessing Mono- and…Transforming Parkinson’s Care in Africa: Establishing a Global Virtual Support Group for Africans Impacted by Parkinson’s Disease
Objective: To establish a monthly Global Virtual Support Group for Africans impacted by Parkinson's disease as part of the Transforming Parkinson’s Care in Africa (TraPCAf)…Safety and Tolerability of Ecopipam in Tourette Syndrome (TS) with Psychiatric Comorbidities.
Objective: Evaluate the effect of ecopipam in children and adolescents with TS on measures of attention deficit disorder (ADHD), anxiety disorders (ANX), obsessive-compulsive disorder (OCD)…Clinical correlates of apathy in Parkinson´s disease
Objective: To investigate the demographic and clinical correlates of apathy in a group of patients from a Movement Disorders clinic in Latin America. Background: Apathy…Longitudinal patterns of Anxiety and Depression in patients with Parkinson’s Disease
Objective: To analyze longitudinal trends of severity of anxiety and depression in a large Parkinson’s Disease (PD) cohort Background: •Depression and anxiety are common non…RBD Unmasked: LRRK2 and the Prodromal Path to Parkinson’s Disease
Objective: The primary objective is to analyze and compare the prevalence of RBD in LRRK2-positive individuals across different stages, including healthy controls (HC), prodromal Parkinson's…Safety and Efficacy of Vatiquinone Treatment in Friedreich Ataxia Patients from MOVE-FA: a Phase 3, Double-blind, Placebo-controlled Trial
Objective: Describe the results of vatiquinone from MOVE-FA (NCT04577352), the 72-week placebo-controlled phase 3 study of patients with Friedreich Ataxia (FA). Background: FA, the most…PreActive-PD Telehealth Coaching to Increase Physical Activity in Early-Stage Parkinson Disease: A Randomized Controlled Feasibility Trial
Objective: To assess the feasibility/acceptability, and preliminary efficacy of Pre-Active PD intervention delivered via telehealth to increase physical activity (PA) engagement in people with early-stage…Role of Wearable Devices in a Physical Activity Coaching Program for People with Parkinson Disease
Objective: Use a mixed-methods approach to evaluate wear-time and physical activity (PA) levels, and explore individual perspectives and feature preferences of people with Parkinson Disease…
- « Previous Page
- 1
- …
- 244
- 245
- 246
- 247
- 248
- …
- 1734
- Next Page »